REG - Nuformix PLC - Posting of Annual Report and Notice of AGM

NuformixAnnouncement

14/02/2025 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250214:nRSN2289Xa&default-theme=true

RNS Number : 2289X  Nuformix PLC  14 February 2025

 

14 February 2025

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual Financial Report for the year ended 30 September 2024 (the "Annual
Financial Report 2024") and the 2025 Notice of Annual General Meeting ("AGM")
are today being posted to its shareholders.

A full pdf version of the Annual Financial Report 2024 together with the
Notice of AGM will shortly be available for download from the Company's
website at: https://nuformix.com/document-center/
(https://nuformix.com/document-center/)

The AGM will be held on 20 March 2025 at 10.00 a.m. at the offices of
Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

 

 Nuformix plc                            Via IFC Advisory

 Dr Daniel Gooding, Executive Director

 CMC Markets                             +44 (0) 20 3003 8632

 Douglas Crippen

 IFC Advisory Limited                    +44 (0) 20 3934 6630

 Tim Metcalfe                            nuformix@investor-focus.co.uk

 Zach Cohen

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com (http://www.nuformix.com)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFLFLSFRISLIE